Treatment of inoperable pancreatic adenocarcinoma with focused ultrasound and microbubbles in patients receiving chemotherapy
Objective: Preclinical trials have demonstrated promising results for increased tumor uptake and therapeutic effect of drugs combined with focused ultrasound (FUS) and microbubbles (MBs). The aim of this clinical trial was to investigate whether FUS and MB could improve the effect of chemotherapy in...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | WFUMB Ultrasound Open |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2949668325000023 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825199230163091456 |
|---|---|
| author | Margrete Haram Rune Hansen Ola Finneng Myhre Stian Solberg Naseh Amini Bjørn Atle Angelsen Catharina de Lange Davies Eva Hofsli |
| author_facet | Margrete Haram Rune Hansen Ola Finneng Myhre Stian Solberg Naseh Amini Bjørn Atle Angelsen Catharina de Lange Davies Eva Hofsli |
| author_sort | Margrete Haram |
| collection | DOAJ |
| description | Objective: Preclinical trials have demonstrated promising results for increased tumor uptake and therapeutic effect of drugs combined with focused ultrasound (FUS) and microbubbles (MBs). The aim of this clinical trial was to investigate whether FUS and MB could improve the effect of chemotherapy in patients with inoperable pancreatic ductal adenocarcinoma (PDAC) and to investigate safety and feasibility. Methods: Twenty patients with inoperable PDAC were included and randomized for either chemotherapy combined with FUS and MBs or only chemotherapy, but one patient in the FUS and MB group had later to be excluded. A new dual-frequency transducer for imaging (4.5 MHz) and treatment (0.35 MHz) was used. After chemotherapy (FOLFIRINOX or nab-paclitaxel-gemcitabine), the treatment group was exposed to FUS (frequency 0.35 MHz, mechanical index 0.5, pulse length 2.9 ms (1000 cycles), pressure amplitude 0.3 MPa and MBs (SonoVue) for 35 min). Nine boluses of MBs were injected intravenously (i.v) with a 3.5 min interval. Patients were scheduled for two months of treatment. Changes in the size of tumors were determined from Computed Tomography (CT) -images. Results: Treatment with FUS and MB is safe with the used settings. No additional effects of FUS and MBs regarding tumor volume or resectability were observed. Overall survival increased, from 9.8 months to 11.7 months for the patients receiving FUS + MB, although not statistically significant. Conclusion: FUS combined with MBs is a safe, feasible, and available strategy for potentially improving the effect of chemotherapy in pancreatic cancer patients. Therapeutic effect was not demonstrated in this trial. Reducing the time between chemotherapy and injection of MB and FUS and optimization of ultrasound parameters may improve the treatment effect. Multicenter trials with standardized protocols should be performed. |
| format | Article |
| id | doaj-art-00dfe3c7fb354c62947f63f5f49fbbed |
| institution | Kabale University |
| issn | 2949-6683 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | WFUMB Ultrasound Open |
| spelling | doaj-art-00dfe3c7fb354c62947f63f5f49fbbed2025-02-08T05:01:47ZengElsevierWFUMB Ultrasound Open2949-66832025-06-0131100080Treatment of inoperable pancreatic adenocarcinoma with focused ultrasound and microbubbles in patients receiving chemotherapyMargrete Haram0Rune Hansen1Ola Finneng Myhre2Stian Solberg3Naseh Amini4Bjørn Atle Angelsen5Catharina de Lange Davies6Eva Hofsli7Department of Radiology and Nuclear Medicine, St. Olav's Hospital - Trondheim University Hospital, Norway; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Norway; Cancer Clinic, St. Olav's Hospital - Trondheim University Hospital, NorwayDepartment of Health Research, SINTEF Digital, Trondheim, Norway; Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, NorwayDepartment of Circulation and Medical Imaging, Norwegian University of Science and Technology, NorwaySURF Technology AS, Trondheim, NorwaySURF Technology AS, Trondheim, NorwaySURF Technology AS, Trondheim, NorwayDepartment of Physics, Norwegian University of Science and Technology, Norway; Corresponding author.Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Norway; Cancer Clinic, St. Olav's Hospital - Trondheim University Hospital, NorwayObjective: Preclinical trials have demonstrated promising results for increased tumor uptake and therapeutic effect of drugs combined with focused ultrasound (FUS) and microbubbles (MBs). The aim of this clinical trial was to investigate whether FUS and MB could improve the effect of chemotherapy in patients with inoperable pancreatic ductal adenocarcinoma (PDAC) and to investigate safety and feasibility. Methods: Twenty patients with inoperable PDAC were included and randomized for either chemotherapy combined with FUS and MBs or only chemotherapy, but one patient in the FUS and MB group had later to be excluded. A new dual-frequency transducer for imaging (4.5 MHz) and treatment (0.35 MHz) was used. After chemotherapy (FOLFIRINOX or nab-paclitaxel-gemcitabine), the treatment group was exposed to FUS (frequency 0.35 MHz, mechanical index 0.5, pulse length 2.9 ms (1000 cycles), pressure amplitude 0.3 MPa and MBs (SonoVue) for 35 min). Nine boluses of MBs were injected intravenously (i.v) with a 3.5 min interval. Patients were scheduled for two months of treatment. Changes in the size of tumors were determined from Computed Tomography (CT) -images. Results: Treatment with FUS and MB is safe with the used settings. No additional effects of FUS and MBs regarding tumor volume or resectability were observed. Overall survival increased, from 9.8 months to 11.7 months for the patients receiving FUS + MB, although not statistically significant. Conclusion: FUS combined with MBs is a safe, feasible, and available strategy for potentially improving the effect of chemotherapy in pancreatic cancer patients. Therapeutic effect was not demonstrated in this trial. Reducing the time between chemotherapy and injection of MB and FUS and optimization of ultrasound parameters may improve the treatment effect. Multicenter trials with standardized protocols should be performed.http://www.sciencedirect.com/science/article/pii/S2949668325000023Pancreatic cancerClinical trialChemotherapyUltrasoundMicrobubblesSonopermeation |
| spellingShingle | Margrete Haram Rune Hansen Ola Finneng Myhre Stian Solberg Naseh Amini Bjørn Atle Angelsen Catharina de Lange Davies Eva Hofsli Treatment of inoperable pancreatic adenocarcinoma with focused ultrasound and microbubbles in patients receiving chemotherapy WFUMB Ultrasound Open Pancreatic cancer Clinical trial Chemotherapy Ultrasound Microbubbles Sonopermeation |
| title | Treatment of inoperable pancreatic adenocarcinoma with focused ultrasound and microbubbles in patients receiving chemotherapy |
| title_full | Treatment of inoperable pancreatic adenocarcinoma with focused ultrasound and microbubbles in patients receiving chemotherapy |
| title_fullStr | Treatment of inoperable pancreatic adenocarcinoma with focused ultrasound and microbubbles in patients receiving chemotherapy |
| title_full_unstemmed | Treatment of inoperable pancreatic adenocarcinoma with focused ultrasound and microbubbles in patients receiving chemotherapy |
| title_short | Treatment of inoperable pancreatic adenocarcinoma with focused ultrasound and microbubbles in patients receiving chemotherapy |
| title_sort | treatment of inoperable pancreatic adenocarcinoma with focused ultrasound and microbubbles in patients receiving chemotherapy |
| topic | Pancreatic cancer Clinical trial Chemotherapy Ultrasound Microbubbles Sonopermeation |
| url | http://www.sciencedirect.com/science/article/pii/S2949668325000023 |
| work_keys_str_mv | AT margreteharam treatmentofinoperablepancreaticadenocarcinomawithfocusedultrasoundandmicrobubblesinpatientsreceivingchemotherapy AT runehansen treatmentofinoperablepancreaticadenocarcinomawithfocusedultrasoundandmicrobubblesinpatientsreceivingchemotherapy AT olafinnengmyhre treatmentofinoperablepancreaticadenocarcinomawithfocusedultrasoundandmicrobubblesinpatientsreceivingchemotherapy AT stiansolberg treatmentofinoperablepancreaticadenocarcinomawithfocusedultrasoundandmicrobubblesinpatientsreceivingchemotherapy AT nasehamini treatmentofinoperablepancreaticadenocarcinomawithfocusedultrasoundandmicrobubblesinpatientsreceivingchemotherapy AT bjørnatleangelsen treatmentofinoperablepancreaticadenocarcinomawithfocusedultrasoundandmicrobubblesinpatientsreceivingchemotherapy AT catharinadelangedavies treatmentofinoperablepancreaticadenocarcinomawithfocusedultrasoundandmicrobubblesinpatientsreceivingchemotherapy AT evahofsli treatmentofinoperablepancreaticadenocarcinomawithfocusedultrasoundandmicrobubblesinpatientsreceivingchemotherapy |